ASCO Audio Journal of Oncology – September 1st, 2006

Mark Socinski

Bruce Johnson

Neil Shah

Doug Smith

Sunitinib Multi-Targeted Oral Anti-Angiogenic Therapy Responses in Lung Cancer

REFERENCE: Abstract 7001Mark A. Socinski, Univerisity of North Carolina, Chapel HillThe use of anti-angiogenic therapy for treating patients with non-small cell lung cancer received a boost at the 2006 ASCO Annual Meeting in Atlanta by results from a study looking at the use of sunitinib, a multi-targeted oral drug that achieved partial responses and stable disease among pretreated patients with non-small cell lung cancer.Mark Socinskifrom the University of North Carolina at Chapel Hill said the results suggest that sunitinib may be even more useful when used in earlier stages of treatment.

Sunitinib in Lung Cancer: Results Assessed

REFERENCE: ABSTRACT 7001, ASCO 2006 Annual Meeting, AtlantaBruce Johnson, Dana-Farber Cancer Institute, BostonDuring the ASCO meeting,Bruce Johnsoncommented on the findings presented byMark Socinski. Peter Goodwin asked him to assess the possible value of sunitinib and the scope of such targeted agents for treating patients with non-small cell lung cancer.

Dasatinib: Possible Option for treating Patients in Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib

REFERENCE: Abstract 6507Neil Shah, University of California, San FranciscoOne of the options for treating patients with chronic phase chronic myeloid leukemia resistant to imatinib might be the new targeted therapy dasatinib. ASCO delegates heard more fromNeil Shah, of the University of California in San Francisco.

Vaccine Promise for Chronic Myeloid Leukemia

REFERENCE: Abstract 6509Doug Smith, Johns Hopkins Cancer Center, BaltimoreA vaccine for chronic myeloid leukemia has produced molecular remissions in a small number of patients. Results were presented at the 2006 ASCO meeting byDoug Smithof Johns Hopkins Cancer Center in Baltimore, who described to Derek Thorne how the vaccine has been performing, and why chronic myeloid leukemia might be a good disease in which to use this approach.